Pharmanomics
How Big Pharma Destroys Global Health
Seiten
2024
Verso Books (Verlag)
978-1-80429-585-4 (ISBN)
Verso Books (Verlag)
978-1-80429-585-4 (ISBN)
- Noch nicht erschienen
- Portofrei ab CHF 40
- Auch auf Rechnung
- Artikel merken
How Big Pharma failed to end a pandemic, and what it tells us about the global economy
In Pharmanomics, investigative journalist Nick Dearden digs down into the way we produce our medicines and finds that Big Pharma is failing us, with catastrophic consequences.
Big Pharma is more interested in profit than health. This was made clear as governments rushed to produce vaccines during the Covid pandemic. Behind the much-trumpeted scientific breakthroughs, major companies found new ways of gouging billions from governments in the West while abandoning the Global South. But this is only the latest episode in a long history of financialising medicine - from Purdue's rapacious marketing of highly addictive OxyContin, through Martin Shkreli's hiking the price of a lifesaving drug, to the 4.5 million South Africans needlessly deprived of HIV/AIDS medication.
Since the 1990s, Big Pharma has gone out of its way to protect its property through the patent system. As a result, the business has focused not on researching new medicines but on building monopolies. This system has helped restructure our economy away from invention and production in order to benefit financial markets. It has fundamentally reshaped the relationship between richer and poorer countries, as the access to new medicines and the permission to manufacture them is ruthlessly policed. In response, Dearden offers a pathway to a fairer, safer system for all.
In Pharmanomics, investigative journalist Nick Dearden digs down into the way we produce our medicines and finds that Big Pharma is failing us, with catastrophic consequences.
Big Pharma is more interested in profit than health. This was made clear as governments rushed to produce vaccines during the Covid pandemic. Behind the much-trumpeted scientific breakthroughs, major companies found new ways of gouging billions from governments in the West while abandoning the Global South. But this is only the latest episode in a long history of financialising medicine - from Purdue's rapacious marketing of highly addictive OxyContin, through Martin Shkreli's hiking the price of a lifesaving drug, to the 4.5 million South Africans needlessly deprived of HIV/AIDS medication.
Since the 1990s, Big Pharma has gone out of its way to protect its property through the patent system. As a result, the business has focused not on researching new medicines but on building monopolies. This system has helped restructure our economy away from invention and production in order to benefit financial markets. It has fundamentally reshaped the relationship between richer and poorer countries, as the access to new medicines and the permission to manufacture them is ruthlessly policed. In response, Dearden offers a pathway to a fairer, safer system for all.
Nick Dearden is the Director of Global Justice Now. He has been a campaigner against corporate globalisation and for global economic justice for over twenty years, working with War on Want, Amnesty International and the Jubilee Debt Campaign. He has been a leading voice in the campaign for a People's Vaccine and a key organiser against neolib- eral trade deals, including the abandoned EU/US Transatlantic Trade and Investment Partnership (TTIP). He regularly contributes political analysis to publications including the Guardian, Al Jazeera, openDemocracy, Red Pepper and Soundings.
| Erscheint lt. Verlag | 17.9.2024 |
|---|---|
| Verlagsort | London |
| Sprache | englisch |
| Maße | 129 x 198 mm |
| Gewicht | 450 g |
| Themenwelt | Sachbuch/Ratgeber ► Gesundheit / Leben / Psychologie |
| Medizin / Pharmazie ► Pharmazie | |
| Recht / Steuern ► EU / Internationales Recht | |
| Recht / Steuern ► Privatrecht / Bürgerliches Recht ► Medizinrecht | |
| Technik | |
| ISBN-10 | 1-80429-585-X / 180429585X |
| ISBN-13 | 978-1-80429-585-4 / 9781804295854 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Vorschriftensammlung
Buch | Softcover (2024)
C.F. Müller (Verlag)
CHF 76,95
